NCT02271347View on ClinicalTrials.gov

An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Ebola Virus
Interventions
DRUG

CMX001

CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY